Search Blog
Categories
October 2019
M T W T F S S
« Sep    
 123456
78910111213
14151617181920
21222324252627
28293031  

Tags

Guangxi to Produce Lithium Oxide for QMC

Corporate Logo

Vancouver, British Columbia–(Newsfile Corp. – October 16, 2019) – QMC Quantum Minerals Corp., (TSXV: QMC) (FSE: 3LQ) (OTC Pink: QMCQF) (“QMC” or “the Company”) announces that it has shipped mineralized samples from the Company’s 100% owned Irgon Lithium Mine Project to China-based Guangxi Non-Ferrous Limu Mining Co., Ltd. (“Guangxi”) to have them test and produce a 6% battery-grade lithium oxide concentrate, under a non-disclosure agreement.

President and CEO Balraj Mann stated “Guangxi has requested we send material to them for metallurgical testing and production of a 6% lithium concentrate. We are excited with this new development as we advance our Irgon Lithium Mine Project forward.” Guangxi is 51% stated-owed by the Guangxi Provincial Government with the balance of ownership being private equity with two processing facilities located in Gongcheng and Lingui, Guilin City, Guangxi, China. Guangxi currently has assets of approximately $1B USD and 500 employees with state-of-the-art ISO-9001:2000 certified analytical testing equipment.

On behalf of Company, SGS Canada has shipped mineralized (spodumene) samples from the Irgon, Irgon West, Mapetre and Central Dikes directly to Guangxi. The shipment consists of pulps (portion of sample prepared for analysis) and previously analyzed samples. QMC will also be shipping an additional larger volume of mineralized sample from the above dikes to Guangxi for further testing. As part of the negotiated agreement between QMC and Guangxi, on completion of the testing process, Guangxi will provide the Company with a report which will include test results and a flow-sheet for the production of concentrate.

Qualified Person

The technical content of this news release has been reviewed and approved by Bruce E. Goad, P. Geo., a qualified person as defined by National Instrument 43-101.

About the Company

QMC is a British Columbia based company engaged in the business of acquisition, exploration and development of resource properties. Its objective is to locate and develop economic precious, base, rare metal resource properties of merit. The Company’s properties include the Irgon Lithium Mine Project and two VMS properties, the Rocky Lake and Rocky-Namew, known collectively as the Namew Lake District Project. Currently, all of the company’s properties are located in Manitoba.

On behalf of the Board of Directors of

QMC QUANTUM MINERALS CORP.

“Balraj Mann”

Balraj Mann

President and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48789

Aurania Reports That Ecuadorian Government Has Replaced the Head of SENAGUA – the Water Authority

Corporate Logo

Aurania Reports That Ecuadorian Government Has Replaced the Head of Senagua – the Water Authority–(Newsfile Corp. – October 16, 2019) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) reports that the Ecuadorian government has replaced the director of SENAGUA, the institution that manages water resources throughout the country. The new Secretary of SENAGUA, Mr. Marco Troya, was appointed by Ecuador’s President Moreno yesterday.

Excessive delays in the issuance of water permits for scout drilling have slowed the rate at which Aurania has been able to drill-test its numerous targets in the Lost Cities – Cutucu Project in southeastern Ecuador. Aurania looks forward to working closely with the new administration towards faster permit approvals under the stringent standards demanded by SENAGUA.

About Aurania

Aurania is a junior mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
Manager – Investor Services
Aurania Resources Ltd.
(416) 367-3200
carolyn.muir@aurania.com
Dr. Richard Spencer
President
Aurania Resources Ltd.
(416) 367-3200
richard.spencer@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48826

SinglePoint Heating Up with New Cannabis Cigarette Launch — CFN Media

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5503/48807_9463560004317999_001full.jpg

Seattle, Washington–(Newsfile Corp. – October 16, 2019) – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article covering

Pure American Hemp cigarettes

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/5503/48807_9463560004317999_001full.jpg

The Pure American Hemp pre-rolls are available in original and menthol in packs of 20 for $19.95. The products are aligned with consumer demand, being organically grown and made of 100% nicotine and tobacco-free hand-selected plants from U.S. family farms.

Click here to see the company corporate presentation

Cash Register Already Ringing

Speaking about the response to showcasing the Pure American Hemp product at NACS, Lambrecht summed it up in saying that the success “was beyond what anybody in our group imagined.” He added “It truly gave us deep insight to how large of an opportunity this is.”

NACS was a premier event to roll-out the product. SinglePoint prepped for the convention with a marketing blitz beforehand introducing the pre-rolls to thousands of buyers at convenience stores around the country. SinglePoint says there is interest from parties representing over 20,000 retail locations already as it taps into a market comprised of in excess of 150,000 c-stores. The company says it has already received “multiple” orders and will be following up with more people in charge of product procurement over the next 90 days to finalize purchase orders.

Likely feeling like he was back in the 1990s when he launched the cigar line, Lambrecht commented, “I am ecstatic to say that again we had people waiting in line to speak about our hemp cigarettes.” Given his past success, Lambrecht being ecstatic is plenty of reason for SING investors to be encouraged about what the new sales channel can mean to revenue, which more than doubled in Q2 from a year earlier to $856,859.

Click here to see the company corporate presentation

SinglePoint will next be meeting with potential buyers and showcasing the Pure American Hemp line at MJBIZCON in Las Vegas on December 11-13.

Please follow the link to read the full article: http://bit.ly/33INc6D

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

About CFN Media

For Visitors and Viewers

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Disclaimer

The above article is sponsored content. Accelerize Inc., which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Contact

SinglePoint
Corporate Communication
SinglePoint Inc.
855-711-2009
investors@SinglePoint.com
SinglePoint.com

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48807

SilverCrest Announces Positive Reconciliation Results for Babicanora Vein, Weighted Average Mined Grade of 2,284 gpt AgEq including;

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/1467/48822_sc1.jpg
  • 2.8 Metres at 15,409 gpt AgEq
  • 4.3 Metres at 7,023 gpt AgEq
  • 3.5 Metres at 6,632 gpt AgEq

Vancouver, British Columbia–(Newsfile Corp. – October 16, 2019) – SilverCrest Metals Inc. (TSX: SIL) (NYSE American: SILV) (“SilverCrest” or the “Company”) is pleased to announce underground (“U/G” ) high-grade vein sampling results showing positive reconciliation compared to the resource model for the Babicanora Vein, in Area 51, of the Las Chispas Project (“Las Chispas”) located in the state of Sonora, Mexico. Reconciliation results between the actual mined vein and the resource model from the U/G mining of the Babicanora Vein along the first 180-metres of vein strike length, or approximately 20% of the mineralized length in Area 51, are shown in the highlights below (see attached Figures).

Highlights of Babicanora Vein Reconciliation (Estimates)

  • Weighted average grade of U/G sampling results in vein:
14.89 gpt Au and 1168.0 gpt Ag, or 2,284 gpt AgEq
  • Estimated grade (cut) of actual mined Babicanora Vein:
15.18 gpt Au and 1071.0 gpt Ag, or 2,209 gpt AgEq
  • Feb. 2019 resource modelled grade (cut) for mined area:
4.48 gpt Au and 556.2 gpt Ag, or 892 gpt AgEq
  • AgEq* grade percent difference between actual versus model:
+147.7%
  • Estimated tonnage of the actual mined Babicanora Vein:
4,170
  • Feb. 2019 resource modelled tonnage for mined area:
6,226
  • Tonnage percent difference between actual versus model:
-33.0%
  • Estimated actual AgEq contained ounces within the mined area:
299,000
  • Feb. 2019 resource modelled AgEq contained ounces in mined area:
179,000
  • AgEq ounce difference between actual versus model:
+65.7%
  • Estimated cut & diluted actual mined & stockpiled:
7,431 tonnes grading 8.62 gpt Au and 613.4 gpt Ag, or 1,259 gpt AgEq for 301,000 AgEq Ounces
  • Cumulative surface stockpiles (new Babicanora Vein and Historic):
182,000 tonnes grading 1.68 gpt Au and 139 gpt Ag, or 264 gpt AgEq for 1,546,000 AgEq Ounces

The positive difference in the actual mined vein and the resource model is based on: 1) the presence of a high-grade clay shear zone within the vein that was not recovered in core drilling during exploration; 2) 25 metre long high-grade portion (3.5 metres wide grading of 5,680 gpt AgEq) of the mined vein that was not intersected in previous exploration drilling; 3) overall, there is more consistency in the quartz-argentite portion of the vein then previously modelled; and 4) less tonnes or vein width means higher grade mineralization which is typical in narrow epithermal-type veins. The 33% decrease in vein resource modeled tonnes (undiluted) based on vein width is noted. In a few areas during drift (development), the vein was only partially mined and future additional excavation may be warranted, after further work. Also noted are high-grade splays trending into the hangingwall and footwall of the Babicanora Vein which may justify excavation after further work. Tonnages and grades will be further reconciled as excavation continues.

A total of 725 U/G channel sample results were used for reconciliation in this news release. Reconciliation results are to be considered only an indication for potential increased grades in the Babicanora Vein and may not be representative of the entire vein. Further work is required to fully understand the grade reconciliation impact. Please see news release dated July 10, 2019 for U/G sampling results of the first 35 metres of vein development used in reconciliation. For the February 2019 resource estimate referred to above including historic stockpiles, please see the technical report titled “Technical Report and Preliminary Economic Assessment for the Las Chispas Property, Sonora, Mexico”, dated effective May 15, 2019, as amended July 19, 2019 (the “PEA”). The PEA is available on SEDAR (

Figure 1: Underground Sampling of Babicanora Vein, Area 51 Zone, Santa Rosa Decline, Level 1096

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/1467/48822_sc2.jpg

Figure 2: Long Section (Inclined) of Area 51 Zone, Babicanora Vein Las Chispas Property, Looking Southwest

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/1467/48822_sc4.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/1467/48822_sc5.jpg

Figure 3: Babicanora Vein Geology & Sample Locations Plan Map 1096 Level, Samples 1.5m above floor, October 2019

To view an enhanced version of Figure 3, please visit:
https://orders.newsfilecorp.com/files/1467/48822_sc6.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/1467/48822_sc7.jpg

Figure 4: Cross Section of Blast #217, AgEq Block Model Comparison for Babicanora Vein Reconciliation (Looking Northwest)

To view an enhanced version of Figure 4, please visit:
https://orders.newsfilecorp.com/files/1467/48822_sc8.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/1467/48822_sc9.jpg

Figure 5: Babicanora Vein, Underground Level 1096, Blast #217, Face Mapping and Sampling (Looking Southeast)

To view an enhanced version of Figure 5, please visit:
https://orders.newsfilecorp.com/files/1467/48822_sc10.jpg


N. Eric Fier, CPG, P.Eng
Chief Executive Officer
SilverCrest Metals Inc.

For Further Information:

SilverCrest Metals Inc.
Contact: Jacy Zerb, Investor Relations Manager
Telephone: +1 (604) 694-1730
Fax: +1 (604) 357-1313
Toll Free: 1-866-691-1730 (Canada & USA)
Email: info@silvercrestmetals.com
Website: www.silvercrestmetals.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48822

Nevada Expansion Latest in String of Big Moves by Plus Products — CFN Media

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5503/48790_58c37a3724085ba6_001full.jpg

Seattle, Washington–(Newsfile Corp. – October 16, 2019) – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article covering

Plus Products

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/5503/48790_58c37a3724085ba6_001full.jpg

In late September, PLUS unveiled three new flavours at the Hall of Flowers cannabis trade show in Santa Rosa, California; Balance Cucumber Lime gummies contain 3.5mg THC and 1.5mg CBD each, while Uplift Tangerine gummies are infused with 5mg THC and <0.1mg CBD; and Unwind Concord Grape gummies have 4.5mg THC and 0.5mg CBD per piece. Plus is currently working on a line of infused chocolates, expected in Q1 2020.

Click here to see the company investor presentation

Further Expansions Coming

As of last year’s mid-term elections, 33 states have legalized cannabis for medical purposes, while ten of them and the District of Columbia have legalized cannabis for recreational adult use. In December, the 2018 Farm Bill was also signed into law, legalizing hemp and the production of hemp-derived CBD, enabling operations in states where other cannabis operations are still illegal. Attitudes are quickly shifting in favour of national legalization, and if that ever comes to fruition, multi-state operators will be better positioned to capitalize.

PLUS intends to expand to 5 additional states by the end of 2020 with Arizona, Illinois, Massachusetts, Michigan, and New York at the top of the list for expansion. The company expects to use a similar partnership model to ensure quality and consistency across markets. At the pace Plus is moving, you’ll definitely want to keep a close eye on them.

Watch this page and visit https://www.plusproducts.com/ for updates.

Please follow the link to read the full article: http://bit.ly/2MHnkRz

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

About CFN Media

For Visitors and Viewers

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Disclaimer

The above article is sponsored content. Accelerize Inc., which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Contact

Plus Products
Blake Brennan
Head of Investor Relations
ir@plusproducts.com
Tel +1 650.223.5478

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48790

Neovasc Retains Westwicke, ICR for Integrated Communications Counsel

Corporate Logo

Company Ramps Up Commercialization of Neovasc Reducer(TM) and Development of Tiara(TM) Product Platforms, Primes for Pivotal Growth Period

Vancouver, British Columbia–(Newsfile Corp. – October 16, 2019) – Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (“Neovasc” or the “Company”), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced it has retained Westwicke, an ICR company (Westwicke, ICR), for integrated investor and public relations consulting services.

“As we advance the development and commercialization of our products, we have engaged Westwicke, ICR to raise our visibility and convey our roadmap for success among key audiences,” said Fred Colen, President and Chief Executive Officer of Neovasc. “We are progressing our EU clinical study for the Transapical Tiara system for minimally invasive treatment of mitral valve disease. We also continue to gain feedback from the U.S. Food and Drug Administration in seeking a Humanitarian Use Device Designation (“HUD Designation”) for Reducer that in a best case scenario, if approved, may provide an expedited pathway to market for the device as an option for patients in the U.S. with the worst angina symptoms. With the $11.5M gross proceeds from our private placement in hand, and Westwicke, ICR’s deep healthcare and medical device industry expertise, we are excited to continue executing on our value creation strategy for shareholders.”

Neovasc continues to drive towards strong double-digit percentage EMEA revenue growth for the Reducer during 2019, with revenue having increased 38% for the first six months this year. In a best-case scenario, contingent on an approved FDA HUD Designation and Human Device Exemption approval, the Company might be able to begin commercializing the Reducer in the U.S. for refractory angina patients suffering from the most severe symptoms in 2020.

In January 2019, ICR, a leading strategic communications and advisory firm, acquired Westwicke Partners, the leading healthcare-focused investor relations firm in North America, combining preeminent healthcare IR with healthcare sector experts in public relations, crisis management, special situations and digital branding.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer (the “Reducer”), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.

About Westwicke Partners

Westwicke Partners provides customized strategic investor relations programs and independent capital markets advice to public and private healthcare companies. Westwicke focuses on the healthcare sector exclusively, and is headquartered in Baltimore with regional offices in Boston, New York, San Diego, San Francisco and London. For more information, please visit www.westwicke.com.

About ICR

Established in 1998, ICR partners with companies to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 550 clients in approximately 20 industries. Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America maintaining offices in New York, Norwalk, Boston, San Francisco and Beijing. ICR also advises on capital markets transactions through its ICR Capital subsidiary. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.

Contacts
Investors:
Mike Cavanaugh
Phone: +1.646.677.1838
Mike.Cavanaugh@westwicke.com
Westwicke, an ICR Company

Media:
Sean Leous
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Westwicke, an ICR Company

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Forward-looking statements may involve, but are not limited to, beliefs and expectations as to a potential expedited approval pathway to market for the Reducer through the US Food and Drug Administration’s Humanitarian Device Designation, potential double-digit percentage EMEA revenue growth for the Reducer during 2019, expectations as to commercializing the Reducer in the US in 2020 and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks relating to the possibility that the Company’s common shares may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange, including Nasdaq’s discretionary public interest authority to apply more stringent criteria for continued listing or suspend or delist securities, which could affect their market price and liquidity; the substantial doubt about the Company’s ability to continue as a going concern; risks relating to the senior secured convertible notes (the “Notes”) issued pursuant to the November 2017 private placement (the “2017 Financing”), resulting in significant dilution to the Company’s shareholders; risks relating to the Company’s need for significant additional future capital and the Company’s ability to raise additional funding; risks relating to cashless exercise and adjustment provisions in the Notes issued pursuant to the 2017 Financing, which could make it more difficult and expensive for the Company to raise additional capital in the future and result in further dilution to investors; risks relating to the sale of a significant number of common shares of the Company; risks relating to the conversion of the senior secured convertible Notes issued pursuant to the 2017 Financing, which may encourage short sales by third parties; risks relating to the Company’s conclusion that it did not have effective internal control over financial reporting as at December 31, 2018; risks relating to the Company’s Common Share price being volatile; risks relating to the influence of significant shareholders of the Company over the Company’s business operations and share price; risks relating to the Company’s significant indebtedness, and its effect on the Company’s financial condition; risks relating to claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company’s resources and result in the payment of significant damages and other remedies; the Company’s ability to establish, maintain and defend intellectual property rights in the Company’s products; risks relating to results from clinical trials of the Company’s products, which may be unfavorable or perceived as unfavorable; the Company’s history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company’s products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more of the Company’s competitors may develop more effective or more affordable products; risks relating to the Company’s ability to achieve or maintain expected levels of market acceptance for the Company’s products, as well as the Company’s ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company’s ability to convince public payors and hospitals to include the Company’s products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation of the Company’s products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company’s products; health and safety risks associated with the Company’s products and industry; risks associated with the Company’s manufacturing operations, including the regulation of the Company’s manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company’s products; risks relating to the manufacturing capacity of third-party manufacturers for the Company’s products, including risks of supply interruptions impacting the Company’s ability to manufacture its own products; risks relating to the Company’s dependence on limited products for substantially all of the Company’s current revenues; risks relating to the Company’s exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company’s employees or agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company’s dependence upon key personnel to achieve its business objectives; the Company’s ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company’s management systems and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company’s ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company’s ability to successfully enter into fundamental transactions as defined in the Notes issued pursuant to the 2017 Financings; anti-takeover provisions in the Company’s constating documents which could discourage a third party from making a takeover bid beneficial to the Company’s shareholders; and risks relating to conflicts of interests among the Company’s officers and directors as a result of their involvement with other issuers. These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Report on Form 20-F and in the Management’s Discussion and Analysis for the three and six months ended June 30, 2019 (copies of which may be obtained at www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48787

HighGold Mining Provides Update on Exploration Program Completion at Johnson Tract, Alaska USA and Other Corporate Activities

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6437/48809_2b00a613345e6a6c_001.jpg

All assays pending for 9-hole drill program at Johnson Tract

Vancouver, British Columbia–(Newsfile Corp. – October 16, 2019) – HighGold Mining Inc. (TSXV: HIGH) (“HighGold” or the “Company“) is pleased to announce the completion of the 2019 Exploration Program (the “Program“) on the Company’s flagship Johnson Tract Gold (Zn-Cu) property (“Johnson” or the “Property“) in Southcentral Alaska. The Program included nine (9) boreholes for 2,247 meters of diamond drilling within the main Johnson Tract deposit (“JT deposit“) as well as a comprehensive field program of prospecting, geological mapping and geochemical sampling on numerous regional targets in the vicinity of the JT deposit. Assay results are pending and will be released in batches.

The main objective of the Program was to confirm, better define and expand the JT deposit, which was drilled by previous operators from 1982 to 1993. HighGold plans to use the new drill data in combination with the validated historic drill data to generate an initial NI43-101 compliant mineral resource for Johnson. The Program was highly successful with all planned work accomplished safely, on time and on budget with a large and significant quantity of field data produced.

“We were able to hit the ground running and execute a highly productive program in a relatively short period of time,” commented HighGold President & CEO Darwin Green. “The work completed has positioned us well to deliver a first-time resource estimate and has reinforced our conviction in the substantial exploration upside at Johnson Tract, which was last explored 25 years ago. We look forward to providing new assay results to the market in the coming weeks as they become available. HighGold was also fortunate to be able to integrate two members of the technical team who were directly involved in the 1980s field programs, providing for the transfer of important historical knowledge and data.”

“After this foreshortened field season, we have come away with an even greater sense of excitement about the exploration potential and have solid exploration targets in hand. While the previous operator did careful and quality work, they were intensely focused on sourcing mill feed for their under-capacity Stewart, B.C mill with budgets that prioritized engineering studies over exploration. Because of this, the Property remains severely underexplored with significant upside exploration potential.”

2019 Exploration Program

Key achievements of the six-week program included:

  • Completion of 2,247 meters of HQ diamond core drilling in nine (9) drill holes (JT19-082 to JT19-090), including the twinning of two historic holes for validation,

  • A total of 1586 drill core samples, 201 rock chip samples and 258 soil and silt samples collected and submitted for assay,

  • Significantly increased understanding of the geological setting and the style and tenor of precious and base metal mineralization and associated alteration and structural framework,

  • Multiple new targets identified for drill testing in 2020,

  • Geological mapping (1:5,000 scale) along the main Johnson Tract-Northeast Offset trend and at the North Alteration Zone, as well as Kona Creek and Difficult Creek prospects [see Figure 1],

  • Geochemical sampling (including rocks, contour soils and stream sediments) at the North Alteration Zone, Kona Creek and Difficult Creek prospects,

  • Review and infill sampling of drill core from ten (10) new and historic holes completed by previous operators, and

  • Collection of specific gravity (“SG”) measurements to bolster the SG database for mineral resource estimation.

Next Steps

The Company plans to move towards an initial mineral resource estimation for the JT deposit once data from the Program has been received and interpreted. First steps will include 3D modeling of geological and mineralized domains and the development of a working geological model for the potential controls on the Au-Cu-Zn-Pb-Ag mineralization. The Company also plans to continue retrieving and compiling historic geological, geochemical and geophysical data collected from 1982 to 1995 by previous operators.

About Johnson Tract Property

The 21,000-acre Johnson Tract property is located near tidewater, 125 miles (200 kilometers) southwest of Anchorage. It includes the very high-grade Johnson Tract Gold (Zn-Cu) deposit along with excellent exploration potential indicated by several other prospects over a 12-kilometer strike length. This project was last explored in the mid-1990s by a mid-tier mining company that evaluated direct shipping ore from Johnson to the Premier Mill near Stewart, British Columbia. HighGold acquired Johnson through a lease agreement with Cook Region Inlet, Inc., an Alaska Native regional corporation that is the largest private landowner within the Cook Inlet region.

Corporate Developments

In addition to its recent listing on the TSX Venture Exchange (see news release dated September 23, 2019), HighGold is making progress toward completion of an application to the Over-the-Counter (OTC) platform in the U.S. While there is no firm timeline to successful completion of this process and quoting on this platform, it is a priority for HighGold’s management team to better serve the existing U.S. shareholders and those who would like to purchase the shares in the United States.

Groundwork and permit applications are also underway to set the stage for drill programs on the Munro-Croesus and Golden Perimeter properties in the Timmins gold camp, Ontario. HighGold anticipates drilling during the first half of 2020 with results being released in meaningful batches throughout the winter and early spring. Additional details will be provided as exploration plans and budgets are finalized.

HighGold has begun a major corporate marketing campaign in North America and Europe, meeting with current and potential institutional shareholders who are focused on high-grade gold projects in safe jurisdictions. A list of upcoming events may be found at
Figure 1 – Trend of district targets to the north and south of the Johnson Tract Deposit

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6437/48809_2b00a613345e6a6c_001full.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48809

ELYSEE earns $935,538 ($0.03 per share) during the nine months ended August 31, 2019

Corporate Logo

Vancouver, British Columbia–(Newsfile Corp. – October 16, 2019) – Elysee Development Corp. (TSXV: ELC) is pleased to announce that its unaudited financial statements and management discussion and analysis for the three and nine months ended August 31, 2019 are now available for viewing on SEDAR and at www.elyseedevelopment.com. All dollar amounts are in Canadian funds.

For the nine month period ending August 31, 2019, the Company earned $935,538 ($0.03 per share) as compared with net earnings of $1,195,025 ($0.06 per share) for the nine months ended August 31, 2018. The earnings for the period were primarily the result of realized gains on marketable securities of $806,281, unrealized gains on marketable securities of $316,485 and interest and dividend income of $150,817.

During the three months ended on August 31, 2019, Elysee earned $232,474 ($0.01 per share) compared to net earnings of $195,474 ($0.01 per share) during the same period a year prior. Total investment income in the third quarter increased to $366,296 from $275,864 for the third quarter of fiscal 2018. The realized gain on securities sold during the current period was $277,377, with an unrealized gain of $43,457 and interest and dividend income of $45,459. General and administrative expenses during the current quarter totalled $133,822 as compared to $80,900 during the same period a year prior. The increase in general and administrative expenses during the current quarter was due to a share-based payments expense of $39,989 (a non-cash item) incurred during the period.

As of August 31, 2019 Elysee’s net asset value (“NAV”) increased to $14,148,783 ($0.53 per share) after paying a one cent per share interim dividend for 2019 in July. The fair value of the company’s investments in marketable securities was $10,103,691 at August 31, 2019, with cash and cash equivalents totaling $1,045,150. The company is debt-free.

Guido Cloetens, the chief executive officer of Elysee, stated: “In the three months ending on August 31, 2019 volatility continued in the junior exploration sector. However, our active investment management policy has allowed us to continue to deliver solid results and maintain a very strong balance sheet. Furthermore, we were still able to increase our net asset value during the period while at the same time paying an interim cash dividend of one cent per share for fiscal 2019 to our shareholders.”

Significant transactions during the three month period ended August 31, 2019 included:

  • the acquisition of 2,800,000 shares of Minera Alamos Inc. at $0.10 per share for $280,000.

  • a subscription for $100,000 to a convertible debenture of WELL Health Technologies Corp. The debenture is convertible at $0.95 per share for 5 years and pays an annual interest rate of 8%.

  • the acquisition of 500,000 units of Southern Silver Exploration Corp. in a private placement at $0.20 per unit for $100,000. Each unit consists of one common share and one warrant, with each warrant entitling the Company to purchase one additional common share of Southern for five years from closing at $0.25 per share.

  • The acquisition for 150,000 shares of Alexco Resource Corp. in a private placement at US$1.00 per share for US$150,000.

  • A subscription for 200,000 shares of Turmalina Metals Corp. in a private placement at $0.50 per share for $100,000; and

  • The acquisition of 250,000 shares of Osisko Mining Inc. in a private placement at $3.15 per share for $787,500.

In June 2019 the Company also took part in a capital raise of U.S. Vanadium Holding Company LLC (“USV”) for an amount of US$375,000. In aggregate, Elysee has now invested US$1.8 million in USV, making it our most significant investment. USV is in the business of sourcing and providing high purity Vanadium Pentoxide (V2O5), technical grade V2O5 and Vanadium Trioxide (V2O3) to customers worldwide. USV recently completed the acquisition of a processing facility in Hot Springs, Arkansas that produces the world’s highest purity vanadium pentoxide (see our news release of October 15, 2019).

The most significant equity investments held by Elysee on August 31, 2019 were US Vanadium Holding Company LLC, Kirkland Lake Gold Ltd., Osisko Mining Inc, Alexco Resource Corp. and TerraX Minerals Inc.

In order to align its reporting periods with those of a number of its private equity investments, the board of directors of Elysee has elected to change its year end to December 31 from November 30. This will be effective for the current fiscal year, which will now end on December 31, 2019.

NAV is a non-GAAP (generally accepted accounting principles) measure calculated as the value of total assets less the value of total liabilities divided by the total number of common shares outstanding as at a specific date. For the purpose of this calculation, share purchase warrants held by Elysee were valued using the Black-Scholes model calculation, as reported in our annual and quarterly financial statements. The term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies. There is no comparable GAAP measure presented in Elysee’s financial statements and thus no applicable quantitative reconciliation for such non-GAAP financial measure. The Company believes that NAV can provide information useful to its shareholders in understanding its performance, and may assist in the evaluation of its business relative to that of its peers.

Shareholders are invited to visit our website www.elyseedevelopment.com on a regular basis for updates.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Stuart Rogers
President
Elysee Development Corp.
Tel: (778) 373-1562

Guido Cloetens
Chairman and CEO
info@elyseedevelopment.com
Tel: (778) 985-8011

Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements – This news release contains certain forward-looking statements that are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward-looking statements, oral or written, made by itself or on its behalf, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48803

Tree of Knowledge International Launches Strategic Partnership for Jamaica and Caribbean Medical Cannabis and CBD Pain Management Research

Corporate Logo

Toronto, Ontario–(Newsfile Corp. – October 16, 2019) – Tree of Knowledge International Corp. (CSE: TOKI) (OTCQB: TOKIF) (Tree of Knowledge) expands global medical marijuana and CBD research in partnership with the Caribbean Institute of Pharmacy Policy (CIPPPAR) in Jamaica. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market. The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments.

A key facet in this partnership will be work with the indigenous communities in Jamaica to identify the above mentioned strains. In addition, Tree of Knowledge and CIPPPAR will work together to develop an international, state-of-the-art medical tourism facility in Jamaica to carry out clinical trials and provide pain management services. The partnership will also create certification and training opportunities for Caribbean doctors, pharmacists, nurses and other medical professionals.

The Honorable Minister Audley Shaw, Minister of Industry, Commerce, Agriculture and Fisheries for Jamaica, has recognized that Jamaica is positioned to play a leading role globally in the development of value added medical cannabis and CBD products. “We welcome companies such as Tree of Knowledge who are committed to invest and transfer knowledge to our leading researchers in Jamaica on the reduction of opioids through cannabis.”

Tree of Knowledge is currently operating in multiple Canadian locations providing education, resources and support to patients and providers across Canada and is excited to be bringing their protocols and learnings to the Caribbean market. “We are very excited with this opportunity to strategically partner with CIPPPAR to help facilitate our shared vision of bringing together expert clinical knowledge, process expertise and available resources to improve the quality of healthcare to patients in Jamaica,” said Gary Prihar, President of Clinical Operations at Tree of Knowledge.

Ellen Grizzle, the former Dean of the University of Technology and head of CIPPPAR, recognized that “this is a significant first step that will lead to future business opportunities throughout the Caribbean.”

Contact:

Tree of Knowledge International Corp.

Natasha Raey
Media Relations
Natasha@tokicorp.com
1.778.552.4538

Michael Caridi
Chairman
Tel: +1 (917) 295-1374
Michael@tokicorp.com

About Tree of Knowledge International Corp.

With its head office in Toronto, and operations in North York, Ontario and Spokane, Washington, TOKI currently has three primary business segments: (1) Multidisciplinary specialty pain clinics with a focus on the treatment of chronic pain, including controlled applications of medical cannabis in Canada, (2) Development of formulated products for therapeutic purposes and natural health product alternatives at its manufacturing facility in Spokane, which provides formulations for the Company’s products and for third parties equivalent to GMP standards, and (3) Distribution and sale of hemp-based cannabidiol (“CBD”) products in the United States, Canada, Europe, Brazil and Australia. Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational clinical trials on medical cannabis and from its ongoing direct patient experience. The Company has developed and implemented MCERP (Medical Cannabis Education, Research and Best Practice Platform) and MCORP (Medical Cannabis Opioid Reduction Program) with great success. Currently, the Company has research agreements with multiple universities for medical cannabis research and new medical grade products development. TOKI’s CBD product line contains EVR Premium Hemp Oil, which is an organically grown and handled, gluten-free, vegan, non-GMO, synergistic compound that is derived from U.S. Department of Agriculture (USDA) approved industrial hemp grown in the United States. TOKI currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes.

Notice Regarding Forward Looking Statements

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include “aimed to reduce stigma in the workplace on the use of cannabis as a medicine”, and “content will also include video resources featuring medical cannabis subject matter experts and fact sheets” . Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including content development and such risks contained in the Company’s annual information form dated June 24, 2019 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48812

TEXTRON DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Textron Inc. To Contact The Firm

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/48816_0901fe3ec4387a6b_001full.jpg

New York, New York–(Newsfile Corp. – October 15, 2019) – Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Textron Inc. (“Textron” or the “Company”) (NYSE: TXT) of the October 21, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi logo

If you invested in Textron stock or options between January 31, 2018 and October 17, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/TXT. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Textron common stock between January 31, 2018 – October 17, 2018 (the “Class Period”). The case, Building Trades Pension Fund of Western Pennsylvania v. Textron Inc. et al., No. 1:19-cv-07881 was filed on August 22, 2019 and has been assigned to District Judge Denise L. Cote.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) end market sales of Arctic Cat products were slowing, resulting in a massive glut of old Arctic Cat inventory on dealers’ floors; (2) in order to clear out this old inventory, the Company provided significant price discounts, which negatively impacted Textron’s earnings; and (3) as a result, Textron’s positive statements about Arctic Cat’s business, operations, and prospects lacked a reasonable basis.

On October 18, 2018, Textron reported weak third quarter 2018 earnings and cut its full-year 2018 forecast. The Company blamed the shortfall on heavy discounts issued by Textron to clear out old inventory. Analysts immediately lowered their price targets on Textron stock citing the inventory concerns at Arctic Cat.

On this news, Textron’s stock fell from $64.78 on October 17, 2018 to $57.49 on October 18, 2018-a $7.29 or 11.25% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Textron’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48816